MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF
暂无分享,去创建一个
[1] S. Thorgeirsson,et al. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression , 2011, Proceedings of the National Academy of Sciences.
[2] R. Basha,et al. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. , 2011, Gynecologic oncology.
[3] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[4] W. Walsh,et al. microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). , 2011, International journal of oncology.
[5] A. Sood,et al. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. , 2011, Neoplasia.
[6] W. Yeo,et al. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. , 2011, International journal of oncology.
[7] M. Abdelrahim,et al. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice , 2011, Investigational New Drugs.
[8] L. Trusolino,et al. MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.
[9] D. Roy,et al. Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. , 2010, The American journal of pathology.
[10] W. Zipfel,et al. Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. , 2010, Translational oncology.
[11] J. Abastado,et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. , 2010, The Journal of clinical investigation.
[12] H. Hermeking,et al. Frequent Downregulation of miR-34 Family in Human Ovarian Cancers , 2010, Clinical Cancer Research.
[13] M. Abdelrahim,et al. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. , 2009, Carcinogenesis.
[14] Ran Kafri,et al. Genetic Redundancy: New Tricks for Old Genes , 2009, Cell.
[15] P. Comoglio,et al. MicroRNAs impair MET-mediated invasive growth. , 2008, Cancer research.
[16] A. Neugut,et al. Mutations in p53, p53 protein overexpression and breast cancer survival , 2008, Journal of Cellular and Molecular Medicine.
[17] R. Weinberg. Leaving home early: reexamination of the canonical models of tumor progression. , 2008, Cancer cell.
[18] Harold Varmus,et al. Seeding and Propagation of Untransformed Mouse Mammary Cells in the Lung , 2008, Science.
[19] L. Trusolino,et al. Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.
[20] R. Place,et al. MicroRNA-373 induces expression of genes with complementary promoter sequences , 2008, Proceedings of the National Academy of Sciences.
[21] W. Zipfel,et al. Toxicity and Biomedical Imaging of Layered Nanohybrids in the Mouse , 2007, Toxicologic pathology.
[22] Wei Wang,et al. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. , 2007, Cancer research.
[23] Ying Feng,et al. Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .
[24] V. Tarasov,et al. Differential Regulation of microRNAs by p53 Revealed by Massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest , 2007, Cell cycle.
[25] L. Lim,et al. A microRNA component of the p53 tumour suppressor network , 2007, Nature.
[26] A. Flesken-Nikitin,et al. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. , 2007, Cancer research.
[27] Michael A. Beer,et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.
[28] A. van Oudenaarden,et al. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. , 2007, Molecular cell.
[29] Moshe Oren,et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. , 2007, Molecular cell.
[30] E. Kistner,et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. , 2007, Cancer research.
[31] R. Place,et al. Small dsRNAs induce transcriptional activation in human cells , 2006, Proceedings of the National Academy of Sciences.
[32] David C. Corney,et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.
[33] P. Kuhn,et al. Immunolocalization of the hepatocyte growth factor (HGF) system in the rat ovary and the anti-apoptotic effect of HGF in rat ovarian granulosa cells in vitro. , 2006, Reproduction.
[34] M. Abdelrahim,et al. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. , 2006, Journal of the National Cancer Institute.
[35] Noam Shomron,et al. Canalization of development by microRNAs , 2006, Nature Genetics.
[36] J. Bergh,et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] F. Dietrich,et al. Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs , 2006, Nature Genetics.
[38] R. Russell,et al. Animal MicroRNAs Confer Robustness to Gene Expression and Have a Significant Impact on 3′UTR Evolution , 2005, Cell.
[39] A. Vaheri,et al. Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. , 2005, Cancer research.
[40] R. Eils,et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. , 2005, Cancer cell.
[41] Z. Werb,et al. Coevolution of cancer and stromal cellular responses. , 2005, Cancer cell.
[42] J. Joyce,et al. Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.
[43] P. Comoglio,et al. Cancer therapy: can the challenge be MET? , 2005, Trends in molecular medicine.
[44] J. Boyd,et al. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. , 2004, Gynecologic oncology.
[45] R. Haba,et al. The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients , 2004, British Journal of Cancer.
[46] A. Nikitin,et al. Pathology of Ovarian Neoplasms in Genetically Modified Mice. , 2004, Comparative medicine.
[47] W. Birchmeier,et al. Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.
[48] S. Mangan,et al. Structure and function of the feed-forward loop network motif , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[49] Brian J. Smith,et al. The impact of p53 protein core domain structural alteration on ovarian cancer survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] C. Marth,et al. Why did p53 gene therapy fail in ovarian cancer? , 2003, The Lancet. Oncology.
[51] A. Flesken-Nikitin,et al. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. , 2003, Cancer research.
[52] D. Rimm,et al. Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors , 2003, Cancer.
[53] A. Berns,et al. Conditional mouse models of sporadic cancer , 2002, Nature Reviews Cancer.
[54] L. Trusolino,et al. Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.
[55] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[56] A. Berns,et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.
[57] P. Leung,et al. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? , 2001, Oncogene.
[58] A. Sood,et al. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma , 2000, Cancer.
[59] A. Berns,et al. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. , 2000, Genes & development.
[60] M. Skinner,et al. Expression and Action of Hepatocyte Growth Factor in Human and Bovine Normal Ovarian Surface Epithelium and Ovarian Cancer1 , 2000, Biology of reproduction.
[61] J. Hayashi,et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. , 1999, Cancer research.
[62] R. Ness,et al. Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.
[63] A. Sood,et al. Distant metastases in ovarian cancer: association with p53 mutations. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[64] W. Lee,et al. Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/- mice. , 1996, Genes & development.
[65] R. Bast,et al. The p53 tumor suppressor gene frequently is altered in gynecologic cancers , 1994, American journal of obstetrics and gynecology.
[66] L. Espey. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. , 1994, Biology of reproduction.
[67] L. Orci,et al. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor , 1991, Cell.
[68] L. Naldini,et al. Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. , 1991, The Journal of biological chemistry.
[69] A. Bardelli,et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. , 1991, The EMBO journal.
[70] W. Birchmeier,et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[71] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[72] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[73] David C. Corney,et al. Role of p53 and Rb in ovarian cancer. , 2008, Advances in experimental medicine and biology.
[74] S. Lai,et al. Spectrum of p53 Tumor Suppressor Gene Mutations and Breast Cancer Survival , 2004, Breast Cancer Research and Treatment.
[75] K. Kinzler,et al. Cancer-susceptibility genes. Gatekeepers and caretakers. , 1997, Nature.
[76] P. Fialkow,et al. Clonal origin of human tumors. , 1979, Annual review of medicine.